AdvertiseDonate
DetroitToledoClevelandFort WayneColumbusPittsburghBuffaloCincinnati
Journal Orbit · 2751 E Jefferson Ave, Suite 400, Detroit, MI 48207

New Daily Pill Offers Major Hope in Pancreatic Cancer Treatment

Early trial results for daraxonrasib show significant tumour shrinkage and potential remission in patients with advanced pancreatic cancer.

By Vanessa Diaz ·

Illustration for: New Daily Pill Offers Major Hope in Pancreatic Cancer Treatment
Illustration generated for this article, not a news photograph.

Medical experts are describing a daily oral medication as the most significant advancement in pancreatic cancer treatment seen in decades. The drug, known as daraxonrasib, appears capable of shrinking tumours and, in some cases, eliminating them entirely from patients who have one of the most lethal and difficult-to-treat forms of cancer.

In early medical trials, cancer became undetectable on scans for approximately one in twelve patients who received daraxonrasib in combination with standard chemotherapy. The study involved 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. For nearly all of these individuals, the tumours ceased growing, offering a stark contrast to the typical progression of the disease.

Despite the promising initial data, doctors caution that the long-term effects remain unclear. It is not yet known how long the treatment can keep the disease at bay, and medical professionals stress that the results should not be interpreted as a definitive cure. The trial followed participants for an average of one and a half years, with some patients experiencing no return of the cancer during this period. Further research is required to determine if these cases represent true remission and to understand the duration of that state.

Cancer Research UK labeled the findings as the biggest leap forward in decades for patients with this condition. Dr Sam Godfrey from the charity told BBC News that the results were incredibly exciting. He noted that the new drug has found a way to target mutations that were previously considered undruggable. According to Dr Godfrey, the medical community is finally seeing progress in pancreatic cancer that has been long overdue.

Pancreatic cancer is notoriously difficult to treat and carries the lowest survival rate among common cancers in the UK. While traditional chemotherapy can sometimes shrink tumours, the cancer frequently regrows. Most patients with advanced disease survive for months rather than years. The new treatment aims to provide patients with more time, even if it cannot permanently stop the cancer from developing.

Specific data from the phase I and II trial indicates that tumours stopped growing in 90% of the patients. Just over 60% of participants saw their tumours shrink or disappear completely. For about 8% of the group, the tumours became undetectable on CT scans. Dr Wungki Park from the Memorial Sloan Kettering Cancer Center in the US, who is involved in the trial, described the results as extremely encouraging. He noted that the study shows higher response rates and deeper responses, along with a near doubling in the duration of disease control, which may eventually lead to longer survival.

Daraxonrasib is a targeted inhibitor that works by locking onto and shutting off specific RAS mutations found in the majority of pancreatic cancers. Because similar mutations appear in dozens of other cancers, including lung and ovarian cancer, the drug could potentially benefit a wider range of patients. Dr Godfrey expressed hope that the early success seen in pancreatic cancer could be extended to other types of malignancy.

The findings are being presented at the EORTC, NCI, and AACR Symposium 2026, a major European cancer conference. Prof Elena Garralda, who chairs the event, stated that the results are exciting because the combined treatment could significantly improve overall survival and the time before tumours begin to grow again. She emphasized the potential for these results to change the outlook for patients facing this aggressive disease.

Pancreatic cancer accounts for about 3% of all cancers in the United States but is responsible for about 8% of all cancer deaths, killing around 53,000 people annually. In Britain, there are 11,500 new diagnoses each year and approximately 10,200 deaths, according to Cancer Research UK. The disease was also the cause of death for actor Alan Rickman in 2016, just five months after his diagnosis. Common symptoms include jaundice, itchy skin, darker urine, paler stools, unexplained weight loss, fatigue, and high temperature.

More World · Report a business · Got a Story?

Get Journal Orbit in your inboxWhat’s happening across America. Free, a few times a week, unsubscribe any time.

Related stories

Latest stories

  1. T-Mobile’s Outsourcing Strategy Is Eroding the Trust of American Customers
  2. New Evidence Leads to Murder Charges in South Carolina Road Rage Case
  3. Top Online Sportsbooks Offer Nearly $4,000 in NBA Betting Promos for Nov. 20
  4. NWSL Championship Matchup Highlights Ongoing Expansion of Women's Soccer
  5. Week 12 College Football: Key Matchups and Betting Lines for the Weekend
Get Journal Orbit in your inboxWhat’s happening across America. Free, a few times a week, unsubscribe any time.